Jiangsu Hengrui
Tracked across 5 events · 57 articles · First seen Apr 22, 2026 · Last active Sep 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Jiangsu Hengrui reported strong Q1 2026 results with significant revenue and net profit growth, driven by innovative drugs and successful business development, including the Nasdaq-100 listing of Kailera Therapeutics.
Apr 22, 2026 · 6 articles
Tech
Impact: Jiangsu Hengrui presented over 90 studies at the ASCO Annual Meeting, showcasing its extensive oncology pipeline and innovative therapies, which could positively impact its market position and future drug approvals.
May 25, 2026 · 33 articles
Business
Impact: Struggling to recruit internationally experienced staff for global clinical trials and commercialization, which may slow overseas expansion.
Jul 15, 2026 · 6 articles
Regulatory
The United States — United States Department of the Treasury is drafting rules governing US pharmaceutical companies' investments in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according…
Impact: The Chinese drugmaker signed a partnership with Bristol Myers Squibb worth up to $15.2 billion, benefiting from continued US licensing activity.
Sep 18, 2026 · 6 articles
Business
Impact: Jiangsu Hengrui is mentioned as a former employer of Beyang's team, adding industry experience but not directly impacted.
Jul 20, 2026 · 6 articles
55
Bristol Myers Squibb signed partnership Jiangsu HengruiUS Treasury Drafts Pharma...
ERGEN INTELLIGENCE
Track Jiangsu Hengrui live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard